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Abstract 
Background: Human chorionic gonadotropin (hCG) can play a crucial role in angiogenesis. In the present study, we 
focused on hCG to gain insight into its potential effects on vasculogenic mimicry (VM) in ovarian cancer cells.
Methods: Ovarian cancer OVCAR-3 cells were incubated with different concentrations of recombinant hCG in 
3-dimensional cultures. VM was identified by morphological observations and vascular endothelial cell marker detec-
tion in OVCAR-3 cells. Expression of hCG, hypoxia-inducible factor-1α (HIF-1α), and the endothelial cell markers CD31, 
VEGF, and factor VIII were detected by reverse transcription polymerase chain reaction and western blotting. The 
effect of hCG on endothelial cell-marker expression in ovarian cancer cells was further explored using small interfering 
RNA (siRNA) and plasmid-based approaches.
Results: Incubation of OVCAR-3 cells with recombinant hCG induced vessel-like network formation, which was 
accompanied by significant elevation of vascular marker expression. Attenuation of hCG expression by siRNA in 
OVCAR-3 cells suppressed the expression of endothelial cell markers and HIF-1α by tumour cells. Overexpression of 
hCG in OVCAR-3 cells resulted in increased expression of endothelial cell markers and HIF-1α.
Conclusions: HCG was crucial for changing the phenotype of OVCAR-3 cells to endothelial-like cells. The effect of 
hCG induction on VM in ovarian cancer cells is potentially associated with HIF-1α.
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Background
The concept of vasculogenic mimicry (VM) was intro-
duced in 1999 and was described as the unique ability 
of highly aggressive melanoma cells to obtain endothe-
lial-like characteristics and form de novo vascular-like 
networks. The aggressive tumor cells have the potential 
to express vascular marker in this novel microcircula-
tion [1]. Tumour cells have direct access to the blood-
stream through the tumour cell-lined vessels and tend to 
spread aggressively due to VM formation [2]. The pres-
ence of VM correlates with an increased risk for metas-
tasis and, therefore, poor clinical outcomes [3]. VM has 
been reported in ovarian cancer, breast cancer, prostate 
cancer, myeloma, hepatocellular carcinoma, Ewing’s sar-
coma, and renal clear cell carcinoma [3–9]. The underly-
ing pathogenic mechanisms of VM are unclear, but the 
influence of the tumour microenvironment is potentially 
associated with VM formation. Hypoxia was reported to 
promote VM formation in 3-dimensional (3D) cultures 
through the hypoxia inducible factor-1α (HIF-1α) path-
way [10, 11].
Choriocarcinoma, which is noted to have high-level 
human chorionic gonadotropin (hCG) production, is 
also characterized by the presence of a multitude of 
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haemorrhagic channels, similar to VM. Recently, we 
reported that ovarian cancer cells can express endothe-
lium-associated genes to form vasculogenic-like net-
works in 3D gels in a microenvironment containing 
added hCG [12, 13]. HCG belongs to a family of glyco-
protein hormones characterized by a heterodimeric 
structure with an α-subunit non-covalently bound to 
the β-subunit, the latter being hormone specific [14]. 
Although β-hCG is normally expressed at detectable lev-
els during pregnancy, it is also ectopically synthesized in 
trophoblastic and non-trophoblastic carcinomas of the 
colon, prostate, bladder, breast, lung, and ovaries [15, 
16]. β-hCG has recently been proposed as a biomarker of 
poor prognosis in cancer [17–19]. It has been suggested 
that placental hCG and vascular endothelial growth fac-
tor (VEGF) interact during formation of the placental 
vasculature [20]. Ectopically produced hCG has recently 
been found to exhibit angiogenic growth factor proper-
ties that are central to cancer progression [16]. β-HCG 
expression in cervical cancer is associated with the extent 
of tumour vascularisation [21]. Serum hCG levels have 
recently been linked to neo-vascularisation of non-sem-
inomatous testicular germ cell tumours [22]. However, 
little has been reported regarding the effects of hCG on 
VM.
We hypothesised that hCG may play a crucial role in 
the development of VM in ovarian cancer. In this study, 
we explored the possible effects of hCG on VM in the 
hCG receptor-positive ovarian cancer cell line OVCAR-3 
in a 3D angiogenesis system. OVCAR-3 cells were incu-
bated with different concentrations of hCG to evaluate 
the influence of hCG on VM formation. HCG receptor-
negative ovarian cancer SKOV3 cells were used as a con-
trol. We identified VM by morphological observations 
and detected vascular marker expression. A small inter-
fering RNA (siRNA) against hCG mRNA and a phCMV1-
derived hCG expression vector were used to gain insight 
into the potential effects of hCG on transendothelial dif-
ferentiation and HIF-1α expression in OVCAR-3 cells.
Results
Vascular cell marker expression and morphological 
flexibility induced by hCG in OVCAR‑3 cells
OVCAR-3 cells were incubated in 3D gels with increas-
ing concentrations of hCG (50, 500, or 5000  mU/ml) 
for 7  days. The expression of vascular cell markers in 
OVCAR-3 cells was analysed by reverse transcription-
polymerase chain reaction (RT-PCR) and western blot-
ting. As shown in Fig. 1a, the expression levels of CD31, 
VEGF, factor VIII mRNA and HIF-1α increased signifi-
cantly in response to hCG treatment, in a dose-depend-
ent manner, as did their respective protein-expression 
levels (Fig. 1b). The highest dose of hCG (5000 mU/ml) 
showed the most significant effect. We also found that 
the relative expression of hCG in OVCAR-3 cells sig-
nificantly increased in response to hCG treatment in a 
dose-dependent manner, compared with that observed in 
unstimulated cells (Fig. 1a–d). However, hCG treatment 
did not significantly increase expression of the vascular 
cell marker in SKOV-3 cells.
OVCAR-3 cells displayed considerable plasticity in 
cell shape when embedded in the 3D matrix under hCG 
treatment when observed by light and scanning-electron 
microscopy. Tubular network and channel formation 
with OVCAR-3 cells were observed in the 3D gel exposed 
to 5000 mU/ml hCG (Fig. 1e). The effects in the 3D gel 
on exposure to 50 or 500  mU/ml hCG with respect to 
morphological changes were not obvious, compared with 
the appearance of untreated cells. SKOV-3 cells failed to 
form tubular networks or channels in the 3D gel, even 
when exposed to 5000 mU/ml hCG.
Inhibition of vascular marker and HIF‑1α expression 
in OVCAR‑3 cells by β‑hCG siRNA
The specificity of the effect of hCG was further assessed 
by down-regulating β-hCG expression with siRNA. 
β-hCG siRNA specifically suppressed hCG expres-
sion. HCG mRNA expression decreased by 71.87  % 
and hCG protein expression decreased by 85.39 %. Our 
data showed that expression of vascular cell markers 
in OVCAR-3 cells was inhibited effectively by β-hCG 
siRNA. For example, expression of CD31, VEGF, factor 
VIII mRNA decreased by 57.36, 77.05, and 86.2 %, respec-
tively, in OVCAR-3 cells transfected with β-hCG siRNA, 
compared with the negative control group. β-hCG siRNA 
also reduced CD31, VEGF, Factor VIII protein expression 
by 82.68, 71.05, and 69.05 %, respectively. HIF-1α mRNA 
and protein expression was also decreased by 69.53 and 
70.61 %, respectively (Fig. 2; p < 0.01).
Expression of vascular markers and HIF‑1α in OVCAR‑3 
cells with up‑regulated β‑hCG expression
To further investigate the effect of hCG on the expression 
of vascular markers in ovarian cancer cells, OVCAR-3 
cells were transfected with the phCMV1 vector express-
ing β-hCG. HCG mRNA and protein expression in 
transfected OVCAR-3 cells was verified by RT-PCR and 
western blot analysis. Compared with parental and vec-
tor control cells, a higher level of hCG expression was 
detected in transfectants overexpressing hCG. HCG 
expression increased by 6.5-fold at the mRNA level and 
2.7-fold at the protein level. The angiogenic efficacy of 
hCG was evaluated by analysing the expression of vas-
cular markers in OVCAR-3 cells overexpressing hCG. 
OVCAR-3 cells transfected with the phCMV1-hCGβ 
vector showed a significant increase in the expression 
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Fig. 2 Inhibition of hCG expression using siRNA resulted in suppressed vascular marker and HIF-1α expression. a, b Expression of hCG in OVCAR-3 
cells was inhibited by siRNA targeting hCG mRNA, but not by a negative control siRNA. Compared with untransfected OVCAR-3 cells and mock-
transfected OVCAR-3 cells, the expression of CD31, VEGF, factor VIII, and HIF-1α decreased in OVCAR-3 cells transfected with hCG siRNA. a mRNA 
expression of the vascular cell marker, HIF-1α and hCG was analysed by RT-PCR. b Protein expression of the vascular cell marker, HIF-1α and hCG was 
analysed by western blotting. c, d Band densities were quantified by densitometric analysis. Protein and mRNA content measured in 3 independent 
replicates was quantified and the data are presented as the mean ± SD. The data shown are presented after normalization with GAPDH bands and 
analysed by 1-way ANOVA. *p < 0.01
(See figure on previous page.)  
Fig. 1 Expression of vascular cell markers and hCG in and morphological flexibility of hCG-treated OVCAR-3 cells. a, b Expression levels of vascular 
markers CD31, VEGF, factor VIII, hCG, and HIF-1α were determined in OVCAR-3 cells exposed to 50, 500, or 5000 mU/ml hCG for 7 days. HCG treat-
ment stimulated the expression of vascular markers and HIF-1α in OVCAR-3 cells in a dose-dependent manner. a The mRNA levels were analysed 
by RT-PCR. b Protein levels were detected by western blotting. c, d Band densities were quantified by densitometric analysis. Protein and mRNA 
content was quantified for 3 independent replicates and the data are presented as the mean ± SD. The data shown are presented after normaliza-
tion with GAPDH expression and were analysed using 1-way ANOVA. *p < 0.01, #p < 0.05. e Light and scanning-electron microscopy observations 
showed tubular network and channel formation by OVCAR-3 cells in the 3D matrix after exposure to 5000 mU/ml hCG. Representative morphologi-
cal changes are shown
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levels of CD31, VEGF, and factor VIII, compared with 
untransfected and mock-transfected cells. Overexpres-
sion of hCG also resulted in a twofold enhancement of 
HIF-1α expression (Fig. 3).
Expression of the hCG receptor (hCG‑R) in OVCAR‑3 cells
We confirmed that the hCG receptor was expressed in 
OVCAR-3 cells by confocal microscopy. The green fluo-
rescence was localized to the periphery of OVCAR-3 cells 
(Fig.  4a). Expression of the hCG receptor in OVCAR-3 
cells exposed to 50, 500, or 5000 mU/ml hCG for 7 days 
were analysed by RT-PCR and western blotting. As 
shown in Fig.  4b–e, treatment of OVCAR-3 cells with 
different hCG concentrations did not significantly affect 
expression of the hCG receptor.
Discussion
VM is the ability of aggressive cancer cells to acquire an 
altered phenotype and form a tumour cell-lined vascu-
lature. The tumour cells can express endothelium-asso-
ciated markers during VM. In tumour vessel channels 
non-endothelial cells have been found to express typical 
endothelial markers as seen in uveal melanoma cells which 
express the endothelial cell markers CD31 and CD34 [23]. 
Fig. 3 Up-regulated expression of vascular markers and HIF-1α in OVCAR-3 cells transfected with the phCMV1 vector expressing β-hCG (phCMV1-
hCGβ). a, b HCG expression increased significantly in transfected OVCAR-3 cells, as determined by RT-PCR and western blot analysis. Compared with 
untransfected and mock-transfected cells, both mRNA (a) and protein expression (b) of CD31, VEGF, Factor VIII, and HIF-1α increased significantly. c, 
d Band densities were quantified by densitometric analysis. Protein and mRNA content measured in 3 independent replicates was quantified and 
the data are presented as the mean ± SD. The data shown were normalized to GAPDH bands and analysed by 1-way ANOVA. *p < 0.01
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Human glioma stem/progenitor cells can transdifferen-
tiate into vascular endothelial cells (VECs) and express 
VECs markers including CD31, CD34, and vWF signifi-
cantly under hypoxia [24]. Von Willebrand factor (VWF), 
a glycoprotein mainly secreted from endothelial cells, is a 
carrier protein of coagulation factor VIII (FVIII). Factor 
VIII-associated antigen are vasculogenic mimicry mark-
ers [25]. VEGF is a major angiogenesis regulator of human 
endothelial cells. VEGF appears to contribute to VM for-
mation in some cancer types including ovarian carcinoma 
[26]. In our study, VM was identified by morphological 
observations and detection of vascular endothelial cell 
markers CD31, VEGF, Factor VIII in ovarian cancer cells.
It has been reported that ovarian cancer SKOV3 cells 
could differentiate into endothelial-like cells and form 
channels on scaffolds in a microenvironment with low 
oxygen tension [2]. Our previous findings showed that 
a microenvironment with hCG localized to scaffolds 
strongly induced VM in hCG receptor-positive ovarian 
cancer OVCAR-3 cells, even under normoxic conditions 
[12].
HCG is a heterodimeric hormone that is primarily pro-
duced by the placenta, but is also produced by other nor-
mal and cancer tissues at low levels [27, 28]. The human 
epithelial ovarian cancer cell line OVCAR-3 not only 
synthesizes hCG, but also expresses hCG receptor on the 
cell membrane. HCG serves a role in angiogenesis both 
in  vivo and in  vitro by increasing capillary formation 
and endothelial cell migration [29–31]. Berndt et al. [32] 
demonstrated a direct angiogenic effect of hCG between 
blastocysts and the maternal endometrium in several 
experimental models. HCG can also facilitate tropho-
blast differentiation [33] and positively influence angio-
genesis by inducing VEGF and matrix metalloproteinase 
9 expression [34]. The angiogenic function of tumour-
derived hCG in VM has not been reported.
The angiogenic activity of hCG was investigated here by 
detecting expression differences in the vascular marker 
and morphological alterations in OVCAR-3 cells in 3D 
gels. The addition of exogenous hCG induced expres-
sion of vascular markers in OVCAR-3 in a dose-depend-
ent manner, with a dose of 5000 mU/ml hCG in 3D gels 
Fig. 4 Expression of the hCG receptor (hCG-R) in the ovarian cancer cell line OVACR-3. a Confocal image of OVCAR-3 cells following immunofluo-
rescence staining with an hCG-R antibody. Green fluorescence was localized to the periphery of OVCAR-3 cells. Blue fluorescence (PI) was used to 
demonstrate the nucleus. b, d Different concentrations of hCG did not significantly affect hCG-R expression in OVCAR-3 cells. b Protein expression 
of hCG-R in OVCAR-3 cells treated with hCG (0, 50, 500, or 5000 mU/ml) for 7 days was detected by western blot analysis. d Expression of hCG-R 
mRNA in OVCAR-3 treated with hCG (50, 500, or 5000 mU/ml) was detected by RT-PCR. c, e Band densities were quantified by densitometric analy-
sis. The protein and mRNA content measured in 3 independent replicates was quantified and the data are presented as the mean ± SD. The data 
shown were normalized to GAPDH bands and analysed using 1-way ANOVA. p > 0.05
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showing the strongest influence on vessel-like tube for-
mation by OVCAR-3 cells. These results indicated that 
hCG potentially affects VM.
In an effort to better understand the involvement of 
hCG in mediating VM in ovarian cancer cells, siRNA was 
used to block hCG expression and study its effect on the 
expression of vascular markers in OVCAR-3 cells. Trans-
fection of the antisense hCG gene resulted in a significant 
inhibition of vascular cell marker expression in OVCAR-3 
cells. OVCAR-3 cells were also transfected with the 
phCMV1 vector, which drove hCG overexpression and 
significantly increased vascular cell marker expression. 
Our data indicated that hCG promotes the trans-differen-
tiation of OVCAR-3 cells into endothelial-like cells.
However, in hCG receptor-negative SKOV3 cells, exog-
enous hCG failed to induce VM formation. These data 
suggested that the hormone may act specifically through 
the hCG receptor. The activity of hCG is initiated by 
binding of hCG to its transmembrane glycoprotein 
receptor, which is a member of the G protein-coupled 
receptor superfamily [35]. Adenylate cyclase on the inter-
nal membrane is then stimulated to convert adenosine 
triphosphate into cyclic adenosine monophosphate [36]. 
Immunofluorescence staining, RT-PCR, and western 
blot data detected stable expression of the hCG receptor 
in the OVCAR-3 cell line. Although OVCAR-3 cells are 
positive for the hCG receptor, treatment of OVCAR-3 
with increasing doses of exogenous hCG had no signifi-
cant effect on expression of the hCG receptor, suggesting 
other possible regulatory pathways involved in the effect 
of hCG [37], which should be a subject of future studies.
We also investigated the effect of hCG on HIF-1α 
expression. Expression of HIF-1α in OVCAR-3 cells 
was up-regulated following hCG treatment or transfec-
tion with the phCMV1 vector, which drove overexpres-
sion of hCG. Conversely, attenuating hCG expression in 
OVCAR-3 cells via siRNA suppressed HIF-1α expres-
sion. HIF-1α is a key transcription factor that mediates 
responses to oxygen deprivation [38]. Hypoxia, an impor-
tant feature of the tumour microenvironment, is known 
to mediate tumour VM through HIF-1α [2, 4]. Driesche 
et  al. [39] demonstrated that HIF-1α expression was 
induced by hCG in luteinizing granulosa cells under both 
hypoxic and normoxic conditions. Our present data indi-
cated that hCG is an important regulator of HIF-1α and 
its downstream target, the vascular marker VEGF [40, 
41]. We propose that hCG may exert its angiogenic effect 
through the HIF-1α-VEGF pathway.
Conclusions
These results may offer new insights into the possible 
regulatory role of hCG in VM formation in ovarian can-
cer. The hCG receptor in OVCAR-3 ovarian cancer cells 
may potentially serve as a novel target in cancer therapy. 
Further studies are required to evaluate the signal trans-
duction pathways involved in the activity of hCG in VM 
of ovarian cancer.
Methods
HCG treatment in 3D cultures
The human epithelial ovarian cancer cell lines OVCAR-3 
and SKOV3 were purchased from the American Type 
Culture Collection (Manassas, VA). One hundred and 
fifty microliters of a co-mixture of Matrigel (Becton–
Dickinson, Bedford, MA) and McCoy-5A/RPMI1640 
(Gibco, Invitrogen, Carlsbad, CA) was dropped onto 
glass coverslips in 24-well culture plates and allowed to 
incubate for 30  min at 37  °C in a humidified 5  % CO2 
incubator. The medium contained 15 % foetal calf serum 
and was changed every 48 h. Tumour cells (1 × 105) were 
seeded onto the gels. Tumour cells were then exposed to 
different concentrations of recombinant hCG (50, 500, or 
5000 mU/ml) for 7 days. HCG was obtained from Sigma 
(St Louis, MO, USA).
RT‑PCR experiments
Total RNA was isolated from the cultured OVCAR-3 
cells using the TRIZOL reagent (Invitrogen, San 
Diego, CA). First-strand cDNA was synthesized 
from 2  μg total RNA using oligo-dT primer (T18) 
and reverse transcriptase (Promega, Southamp-
ton, UK). Amplification of cDNA was performed 
in a PerkinElmer Thermal Cycler (GeneAmp PCR 
Instruments Systems, Roche, Branchburg, NJ). We 
devised primers with the following sequences: β-hCG: 
5′-ACATGGGCATCCAAGGAGC-3′, 5′-GGATTGAGA 
AGCCTTTATTGTGG-3′ (461  bp); hCG receptor: 
5′-TCTATGCCCTATCTGGATTCTAC-3′ and 5′-GGTT 
CCTACTCACGAGGAGTTTA-3′ (156 bp); CD31: 5′-AC 
CAAGATAGCCTCAAAGTCG-3′ and 5′-CCTTCACCC 
TCAGAACCTCAC-3′ (370 bp); VEGF: 5′-TCTGGGCTG 
TTCTCGCTTCGG-3′ and 5′-AGCAGCAAGGCAAGG 
CTCCAAT-3′ (414 bp); factor-VIII: 5′-CCCACCGTTAC 
TGACTCGCTAC-3′ and 5′-ATGCTTTCATGCAGGTT 
TCTCC-3′ (392 bp); HIF-1α: 5′-AAGTGTACCCTAACT 
AGCCG-3′ and 5′-TCACAAATCAGCACCAAGC-3′ 
(161  bp); and GAPDH: 5′-CCATTTGCAGTGGCAAA 
G-3 and 5′-CACCCCATTTGATGTTAGTG-3′ (202 bp). 
PCR amplification was performed using the following 
thermocycling conditions: 95  °C for 5 min, followed by 
40 cycles of denaturation at 94  °C for 1  min, annealing 
at 56 °C for 45 s (hCG), 58 °C for 1 min (hCG-R), 50 °C 
for 45  s (CD31), 60  °C for 45  s (VEGF), 60  °C for 45  s 
(factor VIII), or 60 °C for 30 s (HIF-1α); and then a final 
extension step at 72  °C for 10  min. All amplified prod-
ucts were separated in 1  % agarose gels, and the bands 
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were visualized by ethidium bromide staining. In order 
to semi-quantify the expression level of mRNA, the gels 
were scanned with standard imaging equipment and the 
images were analysed with an image analysis software. 
mRNA contents in the three independent replicates were 
respectively quantified and presented as mean ± SD.
Western blot analysis
Mouse monoclonal antibodies against VEGF, factor VIII, 
β-hCG, hCG receptor, and HIF-1α were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). A 
rabbit monoclonal antibody against CD31 was obtained 
from Bioworld (Dublin, OH). Cellular proteins were 
isolated after rinsing cells with ice-cold phosphate-
buffered saline (PBS; pH 7.4) and lysing them on ice 
with a protein-extraction reagent. The proteins were 
then separated on an 8  % sodium dodecyl sulphide-
Tris polyacrylamide gel. Transfer to a polyvinylidene 
fluoride membrane was performed at 0.27  mA for 2  h. 
The membranes were blocked overnight with 1× Tris-
buffered saline containing 0.1 % Tween 20 and 5 % skim 
milk, followed by incubation with primary antibody 
(1:100) for 1 h and a horseradish peroxidase-conjugated 
secondary antibody (1:1000) for an additional 1  h at 
room temperature. Immunocomplexes were visualized 
by electrochemiluminescence. Protein expression was 
semi-quantified using a Tiannen imager and analysis 
system (Shanghai, China). Protein contents in the three 
independent replicates were respectively quantified and 
presented as mean ± SD.
Immunofluorescence staining and confocal microscopy 
observations
After fixing slides with paraformaldehyde, they were 
rinsed twice in PBST for 5  min. The slides were then 
immersed in 3 % hydrogen peroxide for 20 min to quench 
endogenous peroxidase activity. The specimens were 
pre-blocked for 30  min in bovine albumin serum. Sub-
sequently, the slides were incubated with a rabbit poly-
clonal antibody against the hCG receptor (Santa Cruz, 
CA, USA) at a 1:100 dilution for 1 h at room temperature. 
After washing 3 times in PBS, the slides were incubated 
with a fluorescein isothiocyanate-conjugated anti-rabbit 
immunoglobulin (Santa Cruz, CA, USA) at a 1:100 dilu-
tion for 1 h at room temperature. Negative controls were 
prepared by replacing the primary antibody with Tris-
buffered saline. Samples known to be positive for the hCG 
receptor served as positive controls. A Leica DM IRE2 
confocal laser scanning system (oil immersion objectives 
63´) with a helium ion/green neon laser (543  nm) was 
used. Images were collected and processed using Leica 
confocal software 2.0 and Adobe Photoshop 6.0.
Small interference RNA (siRNA)
HCG siRNAs were synthesized and ligated into the 
PGPU6/GFP/Neo vector by Jima Biologic Technology 
Co. (Shanghai, China). The sequence of pSilencer/β-
hCG was 5′-CCCGAGGTATAAAGCCAGGTACA-3′. 
OVCAR-3 cells were seeded in 6-well plates and grown to 
70–90 % confluency in the absence of antibiotics. Trans-
fections were performed with 0.8 μg of the silencing plas-
mid PGPU6/GFP/Neo-β-hCG and 2  μl Lipofectamine™ 
2000 (Invitrogen, Carlsbad, CA, USA), following the 
manufacturer’s recommended protocol. Control cells 
were mock-transfected. At 24  h post-transfection, the 
transfection efficiency was assessed by fluorescence 
microscopy, revealed that 80 % of the transfectants were 
positive for green fluorescent protein expression. Sta-
bly transfected cells were selected in G418 (0.4  mg/ml; 
Merck, Darmstadt, Germany) for approximately 2 weeks. 
The efficiency of β-hCG silencing was analysed by RT-
PCR and western blotting.
Construction of the phCMV1 vector expressing β‑hCG 
(phCMV1‑hCGβ)
The recombinant phCMV1-hCGβ plasmid was con-
structed based on the phCMV1 vector (Gene Therapy 
System), which encodes the cytomegalovirus mediated-
early promoter plus intron A, followed by the SV40 
polyA expression cassette. The vector expressing hCG 
was generated by cloning the sequences encoding hCG 
into the phCMV1 vector, using unique restriction endo-
nuclease sites. PCR amplification of hCG was per-
formed using the sense primer 5′-CGGAATTCTCC 
AAGGAGCCGCTTCGG-3′ and the antisense primer 
5′-CGGGATCCTTGTGGGAGGATCGG-3′. OVCAR-3 
cells were transfected with 2  μg of DNA using 6  μg 
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA), 
according to the manufacture’s guidelines. The resistant 
clones were selected in G418 (800 μg/ml) for 7 days and 
expanded in 300 μg/ml G418.
Statistical analysis
All experiments were performed at least 3 times. The 
results are presented as the mean ±  standard deviation 
(SD). The data were analysed using SPSS 16.0 for Win-
dows software (SPSS, Inc., Chicago, IL). One-way anal-
ysis of variance (ANOVA) was performed to identify 
statistical differences.
Abbreviations
3D: 3-dimensional; ANOVA: analysis of variance; hCG: human chorionic gon-
adotropin; hCG-R: human chorionic gonadotropin receptor; HIF-1α: hypoxia-
inducible factor-1α; RT-PCR: reverse transcription-polymerase chain reaction; 
siRNA: small interfering RNA; VEGF: vascular endothelial growth factor; VM: 
vasculogenic mimicry.
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